🟢 NanoViricides is trading 5% up in pre-market after Phase II Ebola trial dosing announcement

NanoViricides is trading 5% up now at $1.26 after investors responded positively to the September 15 announcement that its Phase II NV-387 oral-gummy Ebola trial in the Democratic Republic of Congo is scheduled to begin dosing the following week.

• The trial is registered in the Pan African Clinical Trials Registry, supporting expectations for a near-term clinical catalyst.
• Shares previously closed at $1.20 on September 16, following a 14.29% gain.
• The broader pre-market market is also firmer, but the Ebola-trial timeline appears to be the clearest company-specific driver.